This protocol involves the extraction of RNA from retinal and retinal pigment epithelium (RPE) cells in the subject's retina, utilizing TRIzol as the main reagent for cell lysis.
With the present highly infectious dominant SARS-CoV-2 strain of B1.1.529 or Omicron spreading around the globe, there is concern that the COVID-19 pandemic will not end soon and that it will be a race against time until a more contagious and virulent variant emerges. One of the most promising approaches for preventing virus propagation is to maintain continuous high vaccination efficacy among the population, thereby strengthening the population protective effect and preventing the majority of infection in the vaccinated population, as is known to occur with the Omicron variant frequently. Countries must structure vaccination programs in accordance with their populations' susceptibility to infection, optimizing vaccination efforts by delivering vaccines progressively enough to protect the majority of the population. We present a feasibility study proposal for maintaining optimal continuous vaccination by assessing the susceptible population, the decline of vaccine efficacy in the population, and advising booster dosage deployment to maintain the population's protective efficacy through the use of a predictive model. Numerous studies have been conducted in the direction of analyzing vaccine utilization; however, very little study has been conducted to substantiate the optimal deployment of booster dosage vaccination with the help of a predictive model based on machine learning algorithms.
In practically every industry today, artificial intelligence is one of the most effective ways for machines to assist humans. Since its inception, a large number of researchers throughout the globe have been pioneering the application of artificial intelligence in medicine. Although artificial intelligence may seem to be a 21st-century concept, Alan Turing pioneered the first foundation concept in the 1940s. Artificial intelligence in medicine has a huge variety of applications that researchers are continually exploring. The tremendous increase in computer and human resources has hastened progress in the 21st century, and it will continue to do so for many years to come. This review of the literature will highlight the emerging field of artificial intelligence in medicine and its current level of development.
Oncolytic viruses, which may be naturally occurring or genetically engineered, are a type of virus that infects and destroy cancer cells preferentially. Owing to their selectivity, they outperform conventional chemotherapy and radiotherapy, which both have a tendency to impact non-target cells and cause unwanted adverse side effects. Oncolytic virotherapy is a type of cancer treatment in which oncolytic viruses are deliberately introduced into patients affected with cancers in order for them to infect and destroy cancer cells locally or systemically, in a manner analogous to chemotherapy but with a greater degree of selectivity. Multiple studies indicate that oncolytic virotherapy is effective in vitro but in vivo findings remain ambiguous due to the approach's primary limitation: inefficient therapeutic agent delivery to its target, which is heavily influenced by the immune system. Here, we propose overcoming this limitation by exploiting a recent discovery in cancer research: a carrier cell. By exploiting their tumor-promoting activities, mesenchymal stem cells may be employed for cancer therapy by serving as a carrier for the oncolytic viruses toward their target. This approach directly addresses the limitation of conventional oncolytic virotherapy, where oncolytic viruses are often poorly delivered after systemic administration.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.